BERLIN, GERMANY — An investigational RNA interference (RNAi) agent that reduces levels of circulating antithrombin promotes clotting function in people with hemophilia A or B [1]. By depleting ...
Thrombate III is the only antithrombin concentrate approved in both adult and pediatric patients for hereditary antithrombin deficiency. The Food and Drug Administration (FDA) has expanded the ...
Fitusiran antithrombin-based dose regimen targeting 15%-35% of antithrombin activity demonstrated favorable safety profile in male participants aged ≥ 12 years with severe hemophilia A or B, with or ...
BOSTON, Mass., July 16, 2009– Data presented at the annual meeting of the International Society on Thrombosis and Haemostasis (ISTH) in Boston show that ATryn® (Antithrombin [Recombinant]) safely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results